VTVT Stock Analysis: Buy, Sell, or Hold?
VTVT - vTv Therapeutics Inc. Class A Common Stock
$39.25
0.74 (1.92%)
▲
5d:
+5.28%
30d:
+2.86%
90d:
+3.53%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 21, 2026
Get Alerted When VTVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VTVT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VTVT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VTVT is currently trading at $39.25, which is considered extended relative to its 30-day fair value range of $34.84 to $38.28.
Technical Outlook: Technically, VTVT is in a uptrend. The price is approaching resistance at $39.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VTVT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $53.33 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VTVT is in a uptrend. The price is approaching resistance at $39.70. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VTVT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $53.33 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$34.84 -
$38.28
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.5% below Wall St target ($53.33)
Fair Price Analysis
30-Day Fair Range
$34.84 -
$38.28
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$32.86
Resistance Level
$39.70
Current Trend
Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.34
Wall Street Target
$53.33
(+38.5%)
Share & Embed Analysis
Last updated: March 30, 2026 10:27 AM ET
Data refreshes hourly during market hours. Next update: 11:27 AM
Data refreshes hourly during market hours. Next update: 11:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 61 BUY |
